1. India Stocks

  2. •

    Process industries

  3. •

    Chemicals: major diversified
Rite Zone Chemcon India Ltd.

Rite Zone Chemcon India Ltd.

NNSE:RITEZONE
19.50
INR
+0.85
(+4.56%)
61.13MMarket Cap
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
13.59
8.98
11.66
64.12
63.17
61.93
60.38
- -
Basic EPS, GAAP
0.38
0.02
0.54
2.37
2.67
2.11
0.81
- -
Free Cash Flow per Basic Share
-0.65
2.58
-8.56
-11.03
-1.23
-0.13
1.56
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
1.48
1.5
11.86
30.87
33.54
35.66
36.46
36.46
Tangible Book Value per Share
1.48
1.5
11.86
30.87
33.54
35.66
36.46
36.46
Basic Weighted Avg Shares
4
4
4
4
4
4
4
4
Sales/Revenue/Turnover
57
38
49
225
267
262
255
- -
Operating Margin (%)
5.94
2.16
12.17
6.33
7.14
5.38
3.63
- -
Depreciation Expense
2
2
2
3
3
3
3
- -
Net Income, GAAP
2
- -
2
8
11
9
3
- -
Effective Tax Rate (%)
- -
27.73
54.51
23.79
21.97
21.13
39.81
- -
Profit Margin (%)
2.77
0.18
4.65
3.7
4.23
3.41
1.34
- -
Working Capital
16
17
39
119
130
116
120
120
LT Debt
24
32
9
8
7
9
8
8
Total Equity
6
6
50
131
142
151
154
154
Return on Invested Capital (%)
- -
1.64
5.25
8.81
7.31
4.99
1.58
- -
Return on Capital (%)
- -
2.56
5.5
8.93
8.18
6.09
2.45
- -
Return on Common Equity (%)
- -
1.1
8.13
9.18
8.3
6.1
2.24
- -

Capital Structure

INR

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
ST Debt
1
6
8
LT Borrowings
9
8
8
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4
4
4
Market Capitalization
84
99
61

Working Capital

INR

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
Total Current Assets
171
200
183
Cash, Cash Equivalents & STI
1
18
4
Accounts Receivable, Net
127
137
132
Inventories
1
1
1
Total Current Liabilities
55
58
63
Payables & Accruals
- -
- -
- -
ST Debt
1
6
8
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
174.16%
2.26%
Free Cash Flow
- -
-377.06%
-1,284.02%
Net Income, GAAP
- -
686.84%
-61.79%
Sales/Revenue/Turnover
- -
79.95%
-2.5%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
267
2025
- -
- -
262
2026
- -
- -
255

Semi-annual Earnings Per Share

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
2.67
2025
- -
- -
2.11
2026
- -
- -
0.81

Semi-annual Dividends Per Share

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Bhavesh Babulal Bhandari
Full Time Employees
14
Sector
Process industries
Industry
Chemicals: major diversified
Address
T2, JP Imperia Shop Thane India 401107
IPO Date
Nov 11, 2022
Website
ritezone.in
Similar Companies
Hektas Ticaret T.A.S. (BIST:HEKTS)
AARTI Industries Ltd (NSE:AARTIIND)
Aether Industries Ltd. (NSE:AETHER)
Mitsui & Co.,Ltd (TSE:8031)
Saudi Basic Industries Corp. (TADAWUL:2010)
Raghav Productivity Enhancers Ltd. (NSE:RPEL)
Business
Rite Zone Chemcon India Ltd. (RITEZONE.NS) manufactures and sells specialty chemicals for pharmaceutical, agrochemical, polymer, and engineering industries. The company offers a diverse portfolio of products including pharmaceutical intermediates such as cephalosporin active pharmaceutical ingredients (APIs), guaifenesin, and theophylline derivatives; agrochemical intermediates like cypermethrin and lambda-cyhalothrin precursors; polymer additives including brominated flame retardants and UV stabilizers; and engineering chemicals such as heat transfer fluids and corrosion inhibitors. These products are marketed under brands like Rite Zone and Chemcon, targeting domestic pharmaceutical majors, agrochemical exporters, and industrial manufacturers primarily in India, with exports to Southeast Asia, Europe, and the Middle East. Founded in 2018 and headquartered in Ankleshwar, Gujarat, India, the company operates manufacturing facilities in Gujarat's chemical hubs, leveraging backward integration for key intermediates. Rite Zone Chemcon serves B2B customers in the specialty chemicals segment, focusing on high-margin, custom-synthesized molecules for formulations in antibiotics, expectorants, pesticides, and plastics. In the past two years, the company completed a successful initial public offering (IPO) in September 2024, raising funds to expand capacity for cephalosporin APIs and brominated compounds; acquired a strategic stake in a Gujarat-based API facility to enhance backward integration; and launched a new line of green chemistry-based polymer stabilizers amid regulatory shifts toward sustainable chemicals. Recent partnerships include a multi-year supply agreement with a leading Indian generic drug exporter for guaifenesin intermediates and a collaboration with a European agrochemical firm for custom synthesis of insecticide precursors. These developments position Rite Zone Chemcon for revenue growth through increased export volumes and diversified product applications.